Predicting heart failure using the plasma proteome

ABSTRACT

To determine whether the plasma proteome adds value to established predictors in heart failure (HF) with reduced ejection fraction (HFrEF). We sought to derive and validate a plasma proteomic risk score (PRS) for survival in patients with HFrEF (HFrEF-PRS).

Until recently, proteomics had not been as thoroughly explored partly due to comparatively low-throughput. However, emerging proteomic technologies have recently matured and newer high-throughput techniques now allow larger scale proteomic characterization. One of these newer technological innovations, enhanced aptamer-based assays, has enabled a massively expanded candidate approach that borders on true proteomics in scale; thousands of protein-derived factors can be efficiently assayed simultaneously in a small biologic sample. In this webinar, you will explore this new large-scale protein array using an established HF patient registry to understand how the plasma proteome could meaningfully predict the risk of death or HF worsening and add to best conventional risk stratification, including clinical score and natriuretic peptides. By using the circulating proteome to improve risk prediction, it could add a new tool to help manage patients with HF and contribute to discovery of novel HF markers and pathways.

david-headshot

David E. Lanfear, MD, MS, FAHA, FACC, FHFSA

Section Head, Advanced Heart Failure and Transplant Cardiology Co-Director, Center for Individualized and Genomic Medicine Research Professor of Medicine, WSU-SoM Henry Ford Hospital

DAVID E. LANFEAR, MD, MS, Research Professor of Medicine, is Head of the Advanced Heart Failure and Transplant Cardiology at Henry Ford Hospital in Detroit, and Co-Director of the Center for Individualized and Genomic Medicine Research (CIGMA). Dr. Lanfear is a practicing transplant cardiologist, a clinician scientist with a track record of NIH-funded projects on precision medicine and genomics as well as an active trialist with experience in single and multicenter clinical trials. He has more than 140 published manuscripts, reaching high-impact journals including JAMA and NEJM. He is Associate Editor at Circulation: Heart Failure and is on the Editorial Boards of JCF, Heart Failure Reviews, JACC:Cardio-oncology, JACC: Basic to Translational Science.

Share with colleagues

More webinars

WebinarUsing Proteomics To Advance Understanding of Alzheimer’s Disease 

Limited understanding due to its complex pathophysiology and lack of definitive biomarkers currently constrains the diagnosis and treatment of Alzheimer’s disease (AD). But new research is uncovering dynamic brain changes during Alzheimer’s progression, offering potential therapeutic targets. This webinar explores how proteomics and systems biology can be integrated to elucidate AD pathology.

Learn more

WebinarPredictive modeling and reliable biomarker discovery in clinical omics studies 

High-content omic technologies coupled machine learning methods have transformed the biomarker discovery process. However, the translation of computational results into scalable clinical biomarkers remains challenging. A rate-limiting step is the rigorous selection of reliable biomarker candidates among a host of biological features. Drawing examples from real-world clinical omics studies, I will introduce Stabl, a general machine learning framework that identifies a sparse, reliable set of biomarkers by integrating noise injection and a data-driven signal-to-noise threshold into multivariable predictive modeling.

Learn more

WebinarDetecting growing tumors through changes in the plasma proteome 

In this GEN webinar, Nebojsa Janjic, PhD, will discuss the need for a reliable blood-based screening method capable of detecting cancers earlier. During the webinar, he will highlight results from a study involving researchers from SomaLogic and the University of Colorado School of Medicine that used a test capable of measuring 5000 proteins simultaneously.

Learn more

Explore webinars in our interactive viewer